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Research from clinical trials of hormone replacement therapy (HRT) has produced 
conflicting findings about possible risks of dementia after receiving these treatments, and 
further research on HRT and dementia risk has been identified as a priority.  This study will 
investigate risks of incident dementia associated with different types of hormone 
replacement therapy (HRT), using data from two primary care databases (CPRD and 
QResearch). 
Method 
The study design is two nested case-control studies, one in each database.  Cases will be 
women aged 55 years and over with incident dementia diagnosed between 1998 and 
2020, matched with up to 5 controls by age, practice and calendar year.  Cases of 
dementia will be identified in each database using general practice clinical and other 
linked data. The outcome for analysis is incident dementia.  The exposure will be having 
received prescriptions for HRT.  
Analysis  
Exposure to different HRT treatments will be defined as at least one prescription for that 
treatment excluding the three years prior to the index date (date of diagnosis of dementia 
or equivalent date in matched controls).  Conditional logistic regression will be used to 
assess the risks associated with different types of oestrogen and progestogen.  The effects 
of duration, length of any gap since the last use, different application routes and the age 
at which treatment started will be analysed for the most common types of hormones 
used.  All analyses will be adjusted by available data for potential confounding variables. 
Analysis using this same protocol will be carried out using data from each of two primary 
care databases (CPRD and QResearch).  Adjusted odds ratios from the conditional 
regression analyses of the two datasets will be pooled using a fixed effect model with 
inverse variance weights. 
Discussion 
The study findings will show whether receipt of HRT is associated with either an 
increased or decreased risk of subsequent incident dementia.  These results will inform 
future national and international guidance for women and for prescribers. 
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In November 2015, NICE published its first ever guidance on the menopause [1].  The 
menopause occurs when a woman stops having periods – usually a gradual process, 
during which women experience perimenopause before reaching postmenopausal status.  
The average age of menopause in the UK is 51 years but this varies widely, and 1 in 100 
women experience premature ovarian insufficiency (menopause occurring before the age 
of 40 years).  Oestrogen depletion associated with menopause causes irregular periods 
and has many other effects on the body such as hot flushes, night sweats, mood 
changes, memory and concentration loss, vaginal dryness, reduced libido, headaches, 
and joint and muscle stiffness.  Quality of life may be severely affected.  Most women (8 
out of 10) experience some symptoms, typically lasting about 4 years after the last 
period, but continuing in about 10% of women for up to 12 years.  Prolonged lack of 
oestrogen affects the bones and cardiovascular system, and postmenopausal women are 
at increased risk of a number of long-term conditions, such as osteoporosis.  A central 
theme to the NICE guideline is the need for clinicians to provide information on the short 
and longer term risks and benefits of different treatments for menopausal symptoms.  
This includes the effects of non-hormonal treatment such as clonidine as well as different 
types of HRT for women (principally oestrogen and progestogen for women with a 
uterus, and oestrogen alone for women without a uterus).  The guidance distinguishes 
different age groups, such as those under the age of 40, who have had a premature 
menopause due to premature ovarian insufficiency; those undergoing the menopause as 
a result of medical or surgical treatment (including women with cancer); and older 
women experiencing the menopause naturally. 
A woman’s decision to take medication for menopausal symptoms is often influenced by 
high profile studies reported in the media.  The use of HRT halved following the 
publication of two large studies: the Women’s Health Initiative in 2002 [2] and the 
Million Women study in 2003 [3], which found associations between HRT and increased 
risks of breast cancer.  Evidence had also emerged that HRT, rather than having a 
protective effect on the risk of cardiovascular disease as previously thought, might in 
fact be associated with increased risk [4], and the NICE guidance on the menopause was 
developed to respond to concerns about this issue.  Concern about the prospect of 
dementia in older age is growing, so clear information on the associations between 
future risk of dementia and use of HRT will be increasingly important to women 
considering such treatments.  The guideline therefore highlighted investigation into 
associations between the risk of dementia and HRT use as one of its key research 
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recommendations[1].  Media reports about HRT and risks are not always well founded, 
so providing healthcare professionals and women with a robust body of information on 
risk is essential.  While evidence has been improving on some of the risks and benefits of 
HRT (for example, relating to venous thromboembolism[5] and breast cancer[6]), hard 
evidence on how HRT treatments might affect the risk of developing dementia is still 
very uncertain. 
From clinical trials and biological studies, there is evidence that oestrogen may have a 
neuroprotective effect [7] and that HRT initiated soon after the menopause may prevent 
degeneration in crucial brain regions of women at increased risk of dementia (for 
example, those with a history of major depression or with a family history of Alzheimer’s 
disease) [8, 9].  One trial randomised post-menopausal women to either continue or 
discontinue HRT, following them for an average of 2 years use [8].  Of the 54 women 
who remained in the study, 30 stayed on HRT and 24 stopped using HRT.  Comparisons 
of brain images taken at outset and after two years indicated that metabolic activity in 
the medial prefrontal cortex, essential to decision making, seemed better preserved in 
women who had remained on hormone therapy [8].  Of the two HRT drugs taken by 
women in the study (estradiol in pure form and Premarin, a branded drug partly 
comprising estradiol) pure estradiol showed the larger effect in preserving metabolic 
activity [9].  The study size, however, was very small and none of the women in the 
study experienced cognitive decline, making it difficult to draw any firm conclusions [8, 
9].  Conversely the Women’s Health Initiative Study recruited women aged 65 and older 
and found an increased risk of dementia with conjugated equine oestrogen compared 
with placebo as well as an increased risk with combined oestrogen and progestogen [10, 
11].  A recent study used a genomic approach to show that oestrogen loss at menopause 
is likely to contribute to Alzheimer’s disease vulnerability [12].  Some researchers have 
suggested that different types of oestrogen studied may explain this discrepancy while 
others have speculated that there may be a “window of opportunity” for initialisation of 
HRT around the time of the menopause [13]. 
The fact that trial research has so far produced only conflicting findings on the benefits 
or risks of HRT with respect to the development of dementia appears to have inhibited 
further research in the area.  Whatever the reason, the most promising current route for 
investigation seems to be well-powered observational studies – as recommended by 
NICE.  A recent Finnish case-control study, which identified 84,739 women diagnosed 
with Alzheimer’s disease and compared their exposure to HRT with women without a 
diagnosis, found a 9-17% increased risk of Alzheimer’s in HRT users, with no difference 
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between different types of hormones [14].  This study, however, used data from a 
national register, which contained no information about important confounders.  Since 
both general and mental health as well as other drug exposure are related to the 
development of dementia [15, 16], and aspects of these may also be indications for HRT 
prescribing, the overall increased risk of Alzheimer’s disease found in the study might 
reflect confounding due to the association between overall health and indication for HRT 
prescribing. 
The time is ripe, therefore, for a large observational study, which has access to data 
containing as many known risk factors as possible, and which is powered sufficiently to 
consider all the complexities of drug variety, treatment regimes, exposures and patient 
characteristics as possible.  Our proposed study clearly fits these requirements. 
METHODS 
Study design 
We will undertake two nested case control studies with cases of dementia and matched 
controls using two primary care databases QResearch (Version 44) and CPRD (GOLD 
June 2020).  QResearch accumulates records from approximately 1500 English general 
practices, all linked to hospital episode statistics (HES) and Office for National Statistics 
(ONS) mortality data.  CPRD contains information from 771 UK practices (GOLD only) 
with 422 linked to HES and ONS mortality data. 
Information collected by the databases is very similar and contains records for 
consultations, diagnoses and symptoms, tests and prescriptions.  It is, however, 
recorded using different computer systems – EMIS for QResearch and VISION for CPRD 
GOLD.  Although both systems use READ codes for clinical records, recording of ethnicity 
and family history and evaluation of Townsend deprivation scores between the databases 
differ.  Different sets of codes are also used for prescription records. 
Information from these databases is also stored in different locations and cannot be 
pooled.  Two separate studies will therefore be conducted – as similar as possible, 
selecting the same confounders and running the same procedures.  All observations will 
be from general practices in the UK, from the same time period, having similar 
exposures and using similar methods for recording outcomes. 
Definition of the study population 
We will include all practices which have contributed to the databases for at least 10 
years.  The study population will consist of two underlying cohorts of women aged 55 
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and over during the study period (1st January 1998 to 30th June 2020) without a 
diagnosis of dementia at study entry. This age range reflects the mean age of 
menopause in the UK (51 years) to exclude women receiving HRT earlier in life for 
various medical or surgical indications. The study entry date will be defined as at the 
latest of: the study start date (1st January 1998); the practice up to standard date; the 
patient’s date of registration with the practice plus 10 years; the woman’s 55th birthday.  
The cohort will be followed until the earliest of: diagnosis of dementia date; the study 
end date (30th June 2020); the transfer out date; the practice last collection date; 
patient death. 
Selection of cases and controls 
Cases will be women in the cohort who have a first incidence of dementia during the 
observation period, acquired on the earliest date from either the GP record, the hospital 
record or the mortality record.  The diagnosis of dementia will be identified using Read 
and ICD-10 codes for dementia used in previous studies [16].  Linked hospital (HES) 
and mortality data will also be used to identify additional cases with ICD10 diagnoses of 
dementia recorded on hospital records or death certificates.  Additional cases included 
will be those who have received prescriptions for acetylcholinesterase inhibitors 
licensed only for patients with dementia (donepezil, galantamine, memantine, and 
rivastigmine). 
We will match each case with up to 5 controls, who were alive and registered with the 
same practice at the time of the dementia diagnosis of the case.  Controls will be 
matched with cases by practice, age, and calendar time using incidence density 
sampling.  Each control will be allocated an index date which will be the date of first 
diagnosis for the matched case.  Cases and controls will be included only if they have at 
least 10 years of recorded data at the index date, so that exposure to HRT can be 
assessed over a minimum of 7 years (because HRT exposure in the 3 years before 
diagnosis is not being considered). 
Exposures 
We will extract all prescriptions for HRT in cases and controls from the date of patient’s 
registration with the practice up to one year before the index date.  Prescriptions in the 
three years before the index date will not, however, be included for the main analysis to 
reduce protopathic bias.  This is because early symptoms of dementia such as 
depression and sleep disorders might be mistaken for menopause symptoms.  A woman 
will be defined as an HRT user if she has had at least one prescription containing 
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systemic (oral, subcutaneous or transdermal) oestrogen indicated for menopausal 
treatment.  The types of HRT to be included have been identified using the British 
National Formulary section 6.4.1. 
We will consider the types of HRT most commonly prescribed in the UK [6] and 
categorise the exposure by: type of oestrogen (conjugated equine oestrogen or 
estradiol); type of progestogen (medroxyprogesterone, dydrogesterone, norethisterone 
or levonorgestrel/norgestrel); and regimen of use (oestrogen only (or unopposed 
oestrogen) or oestrogen combined with progestogen).  Two types of oestrogen 
(conjugated equine oestrogen and estradiol) will be analysed separately for women 
using oestrogen-only therapy.  Four types of progestogen (medroxyprogesterone, 
dydrogesterone, norethisterone and levonorgestrel/norgestrel) may be prescribed 
either in combination with one of the oestrogens or in addition to an oestrogen-only 
preparation.  The type of oestrogen will not be specified for oestrogen-progestogen 
users. 
We will also categorise HRT by route of delivery – oral or transdermal/subcutaneous.  
Women will be defined as users of oral preparations if they used a tablet formulation of 
HRT, and as users of transdermal/subcutaneous preparations if they used a patch, gel 
formulation or injection of oestrogen, with or without a progestogen.  To account for 
more than one route for a treatment (such as a tablet and a patch) we will have a 
separate variable for each. There is no evidence of increased dementia risk associated 
with other routes of administration (such as cream or vaginal), but they will be 
included into the analysis for consistency and to provide further information on possible 
risks associated with these routes.  Other drugs used for treatment of menopausal 
symptoms – tibolone and clonidine – will also be included as separate variables. 
We will consider the dose for oestrogen which will be categorised into low dose (≤ 
0.625mg for oral equine oestrogen or ≤ 1mg for oral estradiol or ≤ 50 micrograms of 
transdermal estradiol) and high dose (otherwise).  We will analyse the median dose 
across all relevant prescriptions for a woman if she was exposed to both levels. 
Duration of use will be assessed by calculating the number of days of exposure.  If the 
gap between the end of one prescription and the start of the next is 90 days or fewer, 
we will consider exposure as continuous [17, 18] and combine the duration of the 
prescriptions.  We will classify duration as: short-term (up to 1 year); medium-term (1 
to 4 years); long-term (5 to 9 years); very long-term (10 or more years). 
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To address existing speculations that initialisation of HRT around the time of the 
menopause may be beneficial for dementia prevention [13], we will analyse exposures 
by age when HRT treatment was started (<50 years, 50-59 years, 60+ years). 
To investigate the effect of stopping HRT on dementia risk we will assess recency of 
use by calculating the gap in days between the estimated date for last use of HRT and 
the index date, categorising it as either recent use (used between 3 and 5 years before 
the index date) and past use (last use was earlier than 5 years before the index date). 
We will assess exposure at different times by combining duration with recency using 
the categories defined for each.  If the numbers of patients in some category 
combinations are too low, we may collapse some categories. 
For all analyses, no use prior to three years before the index date will be a reference 
category. 
Covariates 
Analyses will be adjusted for patient characteristics, chronic conditions and use of other 
medications which are either risk factors for dementia [15] or indications for HRT use.  
Data for time-related confounders will be extracted at the closest date to 10 years 
before the index date, when they might be more closely associated with initial HRT use. 
Patient characteristics will include: self-assigned ethnicity (using HES and GP data); 
body mass index (continuous); Townsend deprivation score (for the main analysis in 
QResearch and for sensitivity analyses only for CPRD); smoking status (non-smoker; 
ex-smoker; light (light smoker (<10/day), moderate smoker (10-19/day), heavy 
smoker 20+/day)); alcohol consumption (non-drinker, ≤1 unit/day, 2-3 units/day, 4-6 
units/day, 7+ units /day); family history of dementia (yes/no); oophorectomy/ 
hysterectomy (yes/no); premature menopause (yes/no).  Chronic conditions will 
include any record of: anxiety; cancers; coronary heart disease; depression; diabetes; 
hearing loss; hypertension; Parkinson’s disease; stroke. Use of other medications will 
be considered if prescribed at least once at any time before 10 years prior to the index 
date and include: anticholinergic drugs (in particular antidepressants, antiparkinson, 
antipsychotics, antiepileptics and bladder antimuscarinics); antihypertensive; 
benzodiazepines; oral contraceptive; statins. 
Data analysis 
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The main analyses will be run separately on all practices contributing to CPRD and to 
QResearch.  We will use the CPRD study population cohort to calculate incidence rates 
of dementia by dividing the number of incident dementia cases in the cohort by the 
number of person years.  We will present rates by both 5-year age-band and calendar 
year. We will describe characteristics of cases and controls in both cohorts using 
appropriate summary statistics. 
We will use conditional logistic regression in the nested case-control study to estimate 
odds ratios with 95% confidence intervals for the HRT exposure variables.  We will 
calculate unadjusted odds ratios and odds ratios adjusted for potential confounding 
variables listed above. 
To account for missing values, we will use multiple imputation to create ten imputed 
datasets with multiple chained equations, applying Rubin’s rules to combine effect 
estimates and standard errors [19].  The imputation model will include all potentially 
important covariates, outcome status, and years of records [20].  To test our 
assumption that data were missing at random, we will run a sensitivity analysis using 
only records with complete data. 
Adjusted odds ratios from the conditional regression analyses of the two datasets will 
be pooled using a fixed effect model with inverse variance weights.  We will also run a 
sensitivity analysis using a random effect model to allow for any heterogeneity.  
Designing a two database study will not only provide more precise estimates but will 
also increase statistical power to facilitate investigation of less common exposures. 
Using incidence rates in the unexposed CPRD cohort and combined odds ratios, we will 
estimate the absolute and excess risks associated with exposure to different types of 
HRT and for different subgroups of women (55 to 79 years old and 80 years and older). 
To assess incidence rates in unexposed women, we will use the CPRD study population 
cohort but exclude women with prescriptions for HRT before the study entry and follow 
the rest until their first prescription of HRT. 
A 1% level of statistical significance will be used to allow for multiple comparisons. 
Stata 16 will be used for all the analyses. 
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To compare the prevalence rate of HRT captured by routinely collected data with 
existing evidence [21], we will assess the prevalence of HRT exposure in the CPRD 
study population for each year by dividing the number of women with at least one HRT 
prescription by the total number of women, all being registered for the whole year of 
the interest.  The prevalence rates will be presented by 5-year age-band (55-59, 60-
64, 65-69, 70-74, 75 and over) and calendar year. 
To assess whether risks of different types of dementia associated with HRT use vary – 
and to facilitate comparisons with other studies – we will repeat the analyses with two 
subgroups, one restricted to cases diagnosed with Alzheimer’s disease and the other to 
cases with vascular dementia.  We will also run a sensitivity analysis omitting cases 
identified only by prescription for a dementia drug. 
To address consistency in capturing HRT exposure in women of advanced age, we will 
run subgroup analyses for women younger than 80 years and for women 80 years or 
older (at the date of diagnosis of dementia or index date).  We will also run an additional 
analysis on the subgroup of women who had been registered with a practice from their 
50th birthday or earlier. 
For the main analysis, we will include HRT prescriptions recorded up to 3 years before 
the index date, but in a sensitivity analysis we will use all records up to 1 year before 
the index date.  This analysis will be included to investigate the effects of a form of 
selection bias caused by possible under-sampling of exposed cases and controls in the 
main analysis. 
For the main analysis we will assess confounders at 10 years before the index date.  
Since the recording of some of these confounders could be from some time ago, and so 
not be as consistent as more recent data, we will also run a sensitivity analysis where 
confounders will be assessed at three years before the index date. 
For the main analysis we will use all records from QResearch and CPRD.  Because not 
all patients in the CPRD are linked to HES, ONS mortality data and patient-level 
Townsend deprivation index, we will repeat the main analysis on the subgroup of CPRD 
patients linked to these sources of data, also adjusting for the deprivation data. 
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Sample size considerations 
We have interrogated CPRD GOLD using the December 2019 version.  We considered 
patients with first diagnosis of dementia or prescription for dementia aged 55 and over 
between 1 January 1998 and 31st December 2019.  There were 39,862 (18,325 linked) 
such patients with at least 10 years of up to standard (UTS) data. 
To detect an odds ratio of 0.9 with 90% power at the 1% significance level, and 
assuming an exposure prevalence of 10% in controls [6] and correlation of exposure 
between cases and control of 0.1, 19,511 cases would be required, with 5 matched 
controls per case.  To detect an odds ratio of 1.1, 21,814 cases will be required.  For 
rarer exposures of 5%, we will need 37,178 cases for an odds ratio of 0.9 and 41,108 
cases for an odds ratio of 1.1. 
To detect an odds ratio of 0.8 with 90% power at the 1% significance level, and 
assuming a low exposure prevalence of 1% in controls and correlation of exposure 
between cases and control of 0.1, 42,572 cases would be required, with 5 matched 
controls per case.  For an odds ratio of 1.2, 51,181 cases will be required. 
Using QResearch as well as CPRD GOLD will mean that we have easily the required 
number of available cases. This will provide sufficient power to run the proposed 
analyses. 
DISCUSSION 
The study findings will provide important information as to whether HRT is associated 
with either an increase, a decrease or no clinically relevant change in the rate of 
subsequent incident dementia.  This will be important for future guidance of women 
considering HRT and for their doctors.  The results will have international importance. 
The study will have several strengths.  It will be the largest single study, be based on 
the UK general population and will assess risks over a wide range of ages.  Including all 
eligible women – alive or deceased – will make this study free from selection bias.  
Because the information is collected prospectively, the study will be free from recall 
bias.  It will use the most recent information on all prescribed HRT treatments available 
in the UK over the last 20 years.  Long durations of prescribing available in routinely 
collected information will allow the investigation of dosage effects for different types of 
HRT. 
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The limitations of the study will include the lack of formal adjudication of dementia 
diagnoses.  There might be some false positives for cases and some false negatives for 
controls and it is worth noting that, over time, the number of false negatives is likely to 
decrease over time because of improved dementia diagnosis rates.  The likelihood of 
misclassification is much higher for cases than for controls because of the low incidence 
of dementia in the general population.  A systematic review, however, has reported 
that on average 83% of diagnoses of mental and behavioral disorders recorded in 
general practice electronic records were confirmed by other data sources [22].  Also 
using hospital and mortality data for identifying cases will allow us to capture most 
women with dementia diagnoses. 
Another limitation is the potential misclassification of exposure to HRT.  Women can 
access HRT through online prescribing services without seeing their own doctor, but at 
a cost more than three times greater than the prescription fee.  We also do not know 
with certainty whether a woman with a prescription had it filled or whether/when she 
started taking the medication.  Another source of exposure misclassification will mostly 
affect older women, who had their menopause before their practice started contributing 
to the database.  We do not see, however, any reason why these instances should 
differ between cases and controls.  The effects of these potential misclassifications are 
likely to be small, but might shift the odds ratios towards unity. 
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